ArticleScientific reports2024
Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Quantitative molecular cartography of emergency myelopoiesis reveals conserved modules of hematopoietic activation.Cell stem cell · 2026Article
- Identifying and validating of prognostic genes associated with myeloid cell differentiation in cervical cancer: development of a risk model based on single-cell RNA sequencing combined with bulk RNA sequencing data.Translational cancer research · 2026Article
- TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression.Clinical and experimental medicine · 2026Article
- NK cell-associated LncRNA signature predicts prognosis and immune landscape in hepatocellular carcinoma.Clinical and experimental medicine · 2026Article
- Prognostic and immunotherapeutic implications of histamine-related biomarkers in lung adenocarcinoma.PeerJ · 2026Article
- Bibliometric analysis of immune-related acute kidney injury induced by cancer immunotherapy (2000-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A novel defined cuproptosis-related signature score to predict prognosis and immunotherapy efficacy in pancreatic cancer.Oncology letters · 2025Article
- Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA.Discover oncology · 2025Article
- LRP11 as a potential predictor of poor prognosis and immune suppression in lung adenocarcinoma.Discover oncology · 2025Article
- Article
- Subtype-specific causal effects of hypothyroidism on obstructive sleep apnea: A bidirectional Mendelian randomization study.Medicine · 2025Article
- Single‑cell RNA sequencing reveals TMEM71 as an immunomodulatory biomarker predicting immune checkpoint blockade response in breast cancer.Discover oncology · 2025Article
- Development and validation of a basement membrane inflammatory response gene signature in lung adenocarcinoma.Scientific reports · 2025Article
- Integrative transcriptomic and single-cell analysis reveals IL27RA as a key immune regulator and therapeutic indicator in breast cancer.Discover oncology · 2025Article
- Cancer-Derived Extracellular Vesicle ITGB2 Promotes the Progression of Triple-Negative Breast Cancer via the Activation of Cancer-Associated Fibroblasts.Global challenges (Hoboken, NJ) · 2025Article
- Novel immune-nutritional prognostic ratio predicts long-term survival in stage I-III colorectal cancer.Frontiers in oncology · 2025Article
- Mendelian randomization combined with single-cell sequencing analysis revealed prognostic genes related to myeloid cell differentiation in prostate cancer and experimental verification.Frontiers in immunology · 2025Article
- The role of tumor-associated macrophages in lung cancer.Frontiers in immunology · 2025Review
- Elevated BEAN1 expression correlates with poor prognosis, immune evasion, and chemotherapy resistance in rectal adenocarcinoma.Discover oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the key role of myeloid cell differentiation-related genes in the tumor microenvironment (TME), we aimed to build a prognostic risk model using these genes for Lung adenocarcinoma (LUAD). The mRNA gene expression profiles of LUAD patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were downloaded as the training and validation sets. Then, "edgeR" R package was applied to screen out the differentially expressed genes (DEGs) and univariate cox regression, backward stepwise selection analyses were performed to construct a prognostic model for LUAD. ESTIMATE, TIMER, XCELL, CIBERSORT abs, QUANTISEQ, MCPCOUNTER, EPIC, and CIBERSORT algorithms were conducted to access the association of risk levels with the stromal and immune cell infiltration levels in LUAD. Six genes (F2RL1, PRKDC, TNFSF11, INHA, PLA2G3 and TUBB1) were utilized to construct the prognostic model. The risk model showed excellent prognostic performance for LUAD in both TCGA and GEO datasets. Also, compared to the low-risk patients, the high-risk patients had higher expression of immune checkpoint molecules and showed a lower IC50 value to the chemotherapy agents. Our findings provided a myeloid cell differentiation-related gene signature that could effectively predict prognosis and guide treatment strategies for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.